LONDON--()--The US market for Rx-to-OTC switches includes a broad assortment of once proven prescription drugs (Rx) that have acquired the status of being safe and effective as over-the-counter (OTC) products. Factors fuelling the market growth encompass, among others, the world’s aging population, steady-to-increased incidences of conditions and diseases; new drug classes switched to OTC, product demand, and economic environment.
“The U.S. Market for Rx to OTC Switches, 6th Edition”
Competition in the Rx-to-OTC switched universe is expected to remain being moderate, especially with the patent expiration of major products approaching. Consolidation remains part and parcel of the market, with most industry behemoths having made a remarkable acquisition or formed a strategic alliance to increase revenues and drive growth. Product innovation and expansion as well as strong sales support are some of the main growth strategies of the global competitors.
New study “The U.S. Market for Rx to OTC Switches, 6th Edition” developed by Kalorama Information offers a detailed analysis of the US market for drugs with switched ingredients, focusing on several treatment segments with Rx-to-OTC switches in place, besides identifying other areas which may be open to Rx-to-OTC switches in the future.
The report covers statistics for conditions and diseases affecting the country’s population, including detail discussions, tables and figures. Each industry segment is analyzed though product descriptions, market estimates and forecasts, as well as the competitive analysis of the major competitors offering key brand products. In addition, the research is enriched with vital information on the issues and trends affecting the industry today, as well as those that may arise thorough to 2017.
Dominating companies profiled include Bayer Healthcare, Boehringer Ingelheim, GlaxoSmithKline, Insight Pharmaceuticals, Johnson & Johnson, Merck, Novartis, Pfizer, Prestige Brands, Procter & Gamble, Reckitt Benckiser, Sanofi (Chattem), and TEVA.
Title: The U.S. Market for Rx to OTC Switches, 6th Edition
Published: January, 2013
Price: US$ 3,995.00
More Market Research Studies by Kalorama Information Include:
- Worldwide Facial Rejuvenation Markets, 4th Edition
- IVD Procedure Volume and Pricing Analysis
- Food Safety Diagnostics, The World Market
More new studies by Kalorama Information can be found at http://marketpublishers.com/members/kalorama_info/info.html